Literature DB >> 16584509

Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements.

Wiebke Arlt1, Carmen Rosenthal, Stefanie Hahner, Bruno Allolio.   

Abstract

OBJECTIVE: Evaluation of glucocorticoid replacement quality in adrenal insufficiency (AI) relies primarily on clinical judgement and thus largely depends on the physician's expertise. It is a matter of debate whether cortisol day curves are of value in assessing glucocorticoid replacement quality. Here we compared the results of a structured clinical assessment to the outcome of repeated, timed serum cortisol measurements.
DESIGN: Cross-sectional study in the outpatient department of a university teaching hospital. PATIENTS: Forty-six patients (19 men, 27 women, age range 16-76 years) with primary (n = 23) and secondary (n = 23) AI on stable replacement with a median dose of 37.5 mg cortisone acetate (range 25-50 mg) since 10 +/- 7 years (range 1-31 years). MEASUREMENTS: Clinical performance was scored by structured assessment of signs and symptoms, physical examination and routine biochemical tests. Serum cortisol was measured on two to three separate occasions in three timed samples after the morning glucocorticoid dose. Bone mineral density was measured in 15 patients with long-standing glucocorticoid replacement.
RESULTS: Thirty-seven patients were considered well replaced, whereas clinical scores suggested over- or under-replacement in five and four, respectively. There was no correlation of the clinical score with total or body weight-adjusted glucocorticoid dose. The mean z score of serum cortisol differed significantly between under- and over-replaced patients (P < 0.05) but neither group differed significantly from well-replaced patients. Bone mineral density was normal in all patients studied.
CONCLUSIONS: Our results suggest that serum cortisol day curves are of limited value in the monitoring of glucocorticoid replacement. Bone mineral density in AI is generally normal and does not require routine follow-up.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584509     DOI: 10.1111/j.1365-2265.2006.02473.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  28 in total

Review 1.  Anterior pituitary hormone replacement therapy--a clinical review.

Authors:  Christoph J Auernhammer; George Vlotides
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

2.  [Hypopituitarism in adulthood: diagnosis and therapy].

Authors:  Johannes Hensen
Journal:  Med Klin (Munich)       Date:  2009-03-15

3.  Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets.

Authors:  Nicolas Simon; Frederic Castinetti; Floriane Ouliac; Nathalie Lesavre; Thierry Brue; Charles Oliver
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

4.  Global and Targeted Metabolomics Evidence of the Protective Effect of Chinese Patent Medicine Jinkui Shenqi Pill on Adrenal Insufficiency after Acute Glucocorticoid Withdrawal in Rats.

Authors:  Linjing Zhao; Aihua Zhao; Tianlu Chen; Wenlian Chen; Jiajian Liu; Runmin Wei; Jing Su; Xuelan Tang; Keyi Liu; Ran Zhang; Guoxiang Xie; Jun Panee; Mingfeng Qiu; Wei Jia
Journal:  J Proteome Res       Date:  2016-06-20       Impact factor: 4.466

5.  Nocturnal hypoglycemia identified by a continuous glucose monitoring system in patients with primary adrenal insufficiency (Addison's Disease).

Authors:  Gesine Meyer; Annika Hackemann; Juergen Reusch; Klaus Badenhoop
Journal:  Diabetes Technol Ther       Date:  2012-01-13       Impact factor: 6.118

6.  Severe fatigue in patients with adrenal insufficiency: physical, psychosocial and endocrine determinants.

Authors:  V Giebels; H Repping-Wuts; G Bleijenberg; J M Kroese; N Stikkelbroeck; A Hermus
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

Review 7.  Diabetes in Cushing Disease.

Authors:  G Mazziotti; A M Formenti; S Frara; F Maffezzoni; M Doga; A Giustina
Journal:  Curr Diab Rep       Date:  2017-05       Impact factor: 4.810

8.  Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy.

Authors:  Sharon Chan; Miguel Debono
Journal:  Ther Adv Endocrinol Metab       Date:  2010-06       Impact factor: 3.565

9.  Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement.

Authors:  R Giordano; S Marzotti; M Balbo; S Romagnoli; E Marinazzo; R Berardelli; G Migliaretti; A Benso; A Falorni; E Ghigo; E Arvat
Journal:  J Endocrinol Invest       Date:  2009-07-20       Impact factor: 4.256

Review 10.  [Addison's disease : Primary adrenal insufficiency].

Authors:  A Pulzer; S Burger-Stritt; S Hahner
Journal:  Internist (Berl)       Date:  2016-05       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.